Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Updated Pricing Weve restructured our fees to ensure our program remains highly accessiblepassing these cost efficiencies directly to our patients
2 68% of patients were at very high risk for CKD progression 2,k Patient characteristics at baseline (N=3533) 1,2 k Patients were classified as very high risk for CKD progressing according to Kidney Disease: Improving Global Outcomes (KDIGO) risk calculators based on GFR and albuminuria categories
Real medicine, real oversight Compounded by U.S.-licensed pharmacies and prescribed by board-certified clinicians never an algorithm
Retatrutide is an investigational medication not approved by the FDA for routine clinical use
US$ 27.20
US$ 24.67
US$ 22.62
US$ 23.17
US$ 24.84
US$ 25.62
US$ 27.52
US$ 22.21
